You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,180,214


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,180,214
Title:Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image and treat cancers, especially cancers which overexpress GnRH such as breast cancer, prostate cancer and melanoma, among others, including metastatic breast cancer, prostate cancer and/or melanoma among numerous others in vivo. The novel imaging probes are capable of detecting cancerous cells, as well as their metastatic spread in tissues. The novel probes of the present invention will also be useful to initiate therapy for breast and/or prostate cancer, among other cancers, as well as monitor patients\' response to chemotherapy treatments and other interventions or therapies used in the treatment of cancer, including metastatic cancer as otherwise described herein. Compounds according to the present invention may be used as diagnostic tools for diagnosing cancer as well as therapeutic agents for treating cancer and related secondary disease states and conditions.
Inventor(s): Miao; Yubin (Albuquerque, NM)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:13/447,918
Patent Claims:1. A compound according to the chemical structure: ##STR00016## where W is aspartic acid, glutamic acid or pyroglutamic acid; W.sup.2 is serine or threonine; W' is glycine, alanine, leucine, isoleucine or valine; W'' is glycine or alanine; Y is a chelate group selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), Diethylenetriaminopentaacetic acid (DTPA), Mercaptoacetyltriglycine (MAG.sub.3), 4,5-bis(2-mercaptoacetamido)pentanoic, hydrazinonicotinamide/6-hydrazinopyridine-3-carboxylic acid (HYNIC) and HYNIC in combination with tricine or ethylenediaminediacetic acid (EDDA) as a coligand; X is independently an amino acid linker of the chemical structure: ##STR00017## an alkylene oxide group according to the chemical structure: ##STR00018## where each R is independently selected from H or a C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.25 hydrocarbon which is linear, branched or cyclic and which may be optionally saturated or contain one or more unsaturated carbon-carbon bonds, or an amino acid group containing from 1 to about 25 amino acid residues in length, wherein said amino acid residues are selected from the group consisting of glycine, alanine, leucine, isoleucine, valine, serine, threonine, phenylalanine, D-phenylalanine or a mixture thereof; p is an integer from 1 to 25; q is an integer from 1 to 25; r is an integer from 2 to 6; s is an integer from 1 to 25; and z is an integer from 1 to 5, or a pharmaceutically acceptable salt thereof, optionally complexed with at least one radioisotope.

2. The compound according to claim 1 wherein W is glutamic acid or pyroglutamic acid.

3. The compound according to claim 1 wherein W.sup.2 is serine.

4. The compound according to claim 1 wherein W is pyroglutamic acid.

5. The compound according to claim 1 wherein W' is leucine or isoleucine.

6. The compound according to claim 1 wherein W'' is glycine.

7. The compound according to claim 1 wherein said amino acid group comprises amino acid units selected from the group consisting of glycine, alanine, serine or mixtures thererof.

8. The compound according to claim 1 wherein said amino acid group is a polyglycine comprising from 3 to 8 glycine units.

9. The compound according to claim 1 wherein p is 2 to 8.

10. The compound according to claim 1 wherein q is 1 or 2.

11. The compound according to claim 1 wherein q is 1 or 2 when p is 2 to 8 or q is an integer from 5 to 25 when p is 1 or 2.

12. The compound according to claim 1 wherein z is 1 to 5.

13. The compound according to claim 1 wherein Y is a chelate group selected from the group consisting of DOTA, NOTA, MAG3, (HYNIC) and HYNIC in combination with tricine or ethylenediaminediacetic acid (EDDA) as a coligand.

14. The compound according to claim 13 wherein said chelate group is DOTA.

15. The compound according to claim 1 wherein said radioisotope is selected from the group consisting of .sup.86Y, .sup.90Y, .sup.111In, .sup.177Lu, .sup.225Ac, .sup.212Bi, .sup.213Bi, .sup.66Ga, .sup.67Ga, .sup.68Ga, .sup.64Cu, .sup.67Cu, .sup.71As, .sup.72As, .sup.76As, .sup.77As, .sup.65Zn, .sup.48V, .sup.203Pb, .sup.209Pb, .sup.212Pb, .sup.166Ho, .sup.149Pm, .sup.153Sm, .sup.201Tl, .sup.188Re, .sup.186Re and .sup.99mTc.

16. The compound according to claim 15 wherein said radioisotope is polycationic.

17. The compound according to claim 1 wherein said radioisotope is selected from the group consisting of .sup.90Y, .sup.177Lu, .sup.186Re, .sup.188Re, .sup.212Bi/.sup.212Pb, .sup.213Bi, .sup.149Pm, .sup.166Ho and .sup.153Sm.

18. The compound according to claim 1 wherein said radioisotope is selected from the group consisting of .sup.111In, .sup.86Y, .sup.66Ga, .sup.67Ga, .sup.68Ga, .sup.203Pb, .sup.64Cu and .sup.99mTc.

19. A compound of the chemical structure: ##STR00019## where Y is a DOTA chelate group, z is 1, and X is an amino acid linker according to the chemical structure: ##STR00020## or a polyglycine group having between 3 and 6 glycine residues; and w is an integer from 2 to 8; or a pharmaceutically acceptable salt thereof, which is complexed with a radioisotope.

20. The compound according to claim 19 wherein said radioisotope is .sup.111In.

21. The compound according to claim 19 which is ##STR00021##

22. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 complexed with a radioisotope in combination .sub.wi.sub.t h a pharmaceutically acceptable carrier, additive or excipient.

23. The composition according to claim 22 in parenteral dosage form.

24. The composition according to claim 22 in intravenous dosage form.

25. The composition according to claim 22 wherein said compound is combined with at least one additional anticancer agent.

26. The composition according to claim 25 wherein said additional anticancer agent is everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdR.sub.i KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, gleevac, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES (diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258,); vatalanib, AG-013736, AVE-0005, goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW-572016, lonafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, aminoglutethimide, amsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dicarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gemcitabine, gleevac, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291ss, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox, gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonists, palonosetron, aprepitant, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa or a mixtures thereof.

27. A method of diagnosing the existence or absence of cancer in a patient at risk for cancer comprising administering to said patient a compound according to claim 1; imaging said patient to determine if tissue in said patient exhibits elevated expression of GnRH receptors; and diagnosing said patient as having cancer if said tissue evidences elevated expression of GnRH receptors in comparison to a standard.

28. The method according to claim 27 wherein said cancer is a metastatic cancer.

29. The method according to claim 27 wherein said cancer is prostate cancer, ovarian cancer, breast cancer, cervical cancer, uterine cancer, placental cancer melanoma, stomach, colon, rectal, liver, pancreatic, lung, uteri, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney cancer or lymphoma.

30. The method according to claim 27 wherein said imaging is conducted using single photon emission computed tomography (SPECT) and positron emission tomography (PET).

31. A method of treating a cancer which overexpresses GnRH in a patient in need of therapy comprising administering to said patient an effective amount a composition according to claim 22.

32. The method according to claim 31 wherein said cancer is prostate cancer, ovarian cancer, breast cancer, cervical cancer, uterine cancer, placental cancer, melanoma, stomach, colon, rectal, liver, pancreatic, lung, uteri, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney cancer or lymphoma.

33. A method of monitoring therapy of a patient in the treatment of a cancer comprising administering to a patient undergoing cancer treatment an imaging effective amount of a compound according to claim 1, imaging said patient to determine if tissue in said patient exhibits elevated expression of GnRH receptors; and comparing the results of said imaging step with a standard.

Details for Patent 9,180,214

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2031-04-22
Merck Teknika Llc TICE BCG bcg live For Injection 102821 06/21/1989 ⤷  Try a Trial 2031-04-22
Merck Teknika Llc N/A bcg vaccine For Injection 103050 06/21/1989 ⤷  Try a Trial 2031-04-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2031-04-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2031-04-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2031-04-22
Hoffmann-la Roche Inc. ROFERON-A interferon alfa-2a For Injection 103145 06/04/1986 ⤷  Try a Trial 2031-04-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.